St. Jude Medical announces results from POST-IT registry St. Jude Medical announced results from the POST-IT -- Portuguese Study on the Evaluation of FFR Guided Treatment of Coronary Disease -- registry were presented during a hot line late-breaking clinical trial session at EuroPCR 2014. Data from the registry, which was sponsored by the Portuguese Association of Cardiovascular Interventions, demonstrated that the use of St. Jude Medical PressureWire fractional flow reserve technology changed the course of treatment for approximately half of the patients with coronary artery disease, thus ensuring patients with ischemia-producing narrowings received appropriate therapy.
Leerink medical devices analyst holds an analyst/industry conference call Medical Devices Analyst Antalffy discusses the ultimate market opportunity for leadless pacers and compares Medtronic vs St. Jude Medical on an Analyst/Industry conference call to be held on September 24 at 2 pm.
St. Jude Medical recent weakness a buying opportunity, says Barclays Barclays said St. Jude Medical weakness is a buying opportunity. The analyst said CardioMEMS is underappreciated by the Street and valuation compelling given sequential revenue growth. Shares are Overweight rated.